Longevity.Technology maps gray market driving BPC-157 and GLP-1 demand
The piece frames unapproved research peptides and incretin drugs as two halves of a fast-growing and loosely policed market.
TR
By Tom Reyes · Markets Editor
Oct 5 07:43 ETSource: Longevity.Technology
The wire
- 01Longevity.Technology examines the surge in consumer demand for peptides including BPC-157 alongside GLP-1 drugs, and the gray-market supply that has grown with it.
- 02Telehealth operators and clinics competing with research-chemical sellers face the sourcing and legitimacy questions the article raises.
- 03This is trade commentary rather than new data or regulatory action, and it does not quantify the size of the unregulated channel.
From the source
Read at longevity.technologyBPC-157, GLP-1s and the New Peptide Gold Rush
